A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...
Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...
Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...
Alterations in the tumour suppressor genes STK11 and/or KEAP1 can identify patients with advanced non-small-cell lung cancer who are likely to benefit from combinations of PD-(L)1 and CTLA4 immune ...
harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus ...
Oct. 8, 2024 — Engineers built a solar-powered desalination system that produces large quantities of clean water despite variations in sunlight throughout the day. Because it requires no extra ...
BerGenBio announces safety data from phase 1b portion of BGBC016 study in first-line NSCLC: Bergen, Norway Tuesday, October 8, 2024, 15:00 Hrs [IST] BerGenBio ASA, a clinical-stag ...
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback